Chondroid Lipoma
Chondroid lipoma is an extremely rare benign variant of lipoma that reflects metaplastic growth of fatty tissue. Under the microscope it combines mature fat cells with chondroblast-like cells and pseudolipoblasts, all set in a myxoid-chondroid matrix rich in mucopolysaccharides.
The word "chondroid" and the microscopic pseudolipoblasts can lead to serious confusion on pathology with malignant or borderline tumors such as myxoid liposarcoma, extraskeletal myxoid chondrosarcoma or a benign mixed tumor (myoepithelioma). Despite its complex appearance, which imitates both cartilage and embryonic fat, chondroid lipoma is entirely benign. It mainly affects middle-aged women, arises in the deep tissues of the limbs and limb girdles, and is cured once it has been completely excised.
At Haute-Derma, we follow a standardized pathway for chondroid lipoma: careful histological review combined with an immunohistochemical and molecular panel (S100/CD68/MDM2), detailed 3.0T MRI, and microsurgical removal of the tumor with its intact capsule, so the lesion is fully treated and patients can be confident about the outcome.
Pathology and Classification
Causes and Molecular Genetics
- Characteristic translocation t(11;16)(q13;p13):
- Chondroid lipoma is defined by the chromosomal translocation t(11;16)(q13;p13), which creates the C11orf95-MAML2 fusion gene (a MAML2 rearrangement).
- This change is entirely distinct from the FUS-DDIT3 fusion of myxoid liposarcoma and the EWSR1-NR4A3 fusion of myxoid chondrosarcoma, confirming that chondroid lipoma is a separate, benign entity.
- Who gets it and where:
- Mostly women (female-to-male ratio about 4:1), usually aged 30–60.
- Typical sites: deep subcutaneous tissue or muscle of the limbs (thigh, lower leg, upper arm) and limb girdles (shoulder, hip). The lump is usually painless, well defined and slow-growing.
Histopathology: The Gold Standard
Under the microscope, chondroid lipoma shows a characteristic mix of three core components:
- Chondroblast-like cells and pseudolipoblasts: round, polygonal or spindle-shaped cells with small lipid vacuoles in the cytoplasm (multivacuolar cytoplasm) that gently push the nucleus to the center. They sit in lacunae and closely resemble primitive cartilage cells or lipoblasts. The nuclei are round and uniform, with no atypical mitoses or bizarre hyperchromatic nuclei.
- Myxoid-chondroid matrix: a connective tissue background that stains deep blue with Alcian blue (rich in chondroitin sulfate), mimicking hyaline cartilage.
- Mature adipocytes: lobules of mature fat scattered around the edges or within the chondroid matrix.
Differential Diagnosis and Immunohistochemistry (IHC)
Because the chondroid-myxoid background is easily mistaken for dangerous malignant tumors, the comparison below is the gold standard:
| Condition | Immunohistochemical Markers (IHC) | Distinguishing Microscopic Features |
|---|---|---|
| Chondroid lipoma | S100 (+); CD68 (+); cytokeratin (−); SMA (−); MDM2 (−) | Alcian blue-positive chondroid-myxoid matrix; pseudolipoblasts within lacunae; no atypical mitoses. |
| Myxoid liposarcoma | FUS-DDIT3 (+); S100 (+/−); CD68 (−) | "Chicken-wire" capillary network; malignant lipoblasts; no true cartilaginous differentiation. |
| Extraskeletal myxoid chondrosarcoma (EMC) | NR4A3 rearrangement (+); S100 (−) or weak; CD68 (−) | Cords and nets of cells in an abundant myxoid background; no mature fat cells at all. |
| Benign mixed tumor / myoepithelioma | Cytokeratin (+); EMA (+); SMA (+); S100 (+) | Proliferating myoepithelial cells; no mature fat lobules and no t(11;16) translocation. |
Our Approach to Treating Chondroid Lipoma
Haute-Derma manages chondroid lipoma on three principles: immunohistochemical confirmation, 3D imaging, and microsurgical removal of the tumor with its capsule intact:
- Confirming benign nature with an IHC panel: we look for S100 (+) and CD68 (+) with negative cytokeratin, SMA and MDM2. Confirming MDM2 (−) and the absence of the FUS-DDIT3 fusion rules out myxoid liposarcoma with certainty, sparing the patient a wide, muscle-destroying resection.
- Complete encapsulated excision under microsurgery: because chondroid lipoma has a complete fibrous capsule, removing it whole microsurgically achieves a 100% cure rate.
- Preserving limb function: the tumor often lies deep near the muscle fascia, so the surgeon carefully separates it from the surrounding muscle fibers and nearby motor nerve bundles.
How We Diagnose Chondroid Lipoma at Haute-Derma
- Clinical examination and assessment of depth: we assess lumps on the thigh, upper arm or shoulder in middle-aged women. The tumor usually feels slightly firm and well defined, and moves less than a superficial lipoma because it lies beneath the muscle fascia.
- High-resolution 3.0T MRI: the tumor shows low-to-intermediate signal on T1-weighted images and very bright signal on T2-weighted images (because the myxoid-chondroid component holds a lot of water), with thin fibrous septa that enhance with contrast. MRI defines exactly how the tumor relates to the fascia and major blood vessels.
- Core needle biopsy with mandatory IHC: tissue is examined with H&E staining (to identify the chondroid matrix and pseudolipoblasts), an immunohistochemical panel (S100, CD68, cytokeratin, MDM2) and a special Alcian blue stain to confirm the diagnosis.
Specialist Treatment at Haute-Derma
- Microsurgical enucleation:
- Indication: the only gold-standard treatment for chondroid lipoma.
- Technique: a small incision hidden along a natural skin crease of the limb, followed by dissection through the fascia to reach the capsule. The surgeon removes the whole tumor together with its fibrous capsule, leaving the muscle fibers and nearby motor nerve branches fully intact.
- Functional recovery and scar care: the fascia and subcutaneous tissue are repaired in several layers to prevent muscle herniation. Anti-inflammatory He-Ne laser supports wound healing, and fractional CO2 laser is used to soften the surgical scar.
- Scheduled follow-up: ultrasound or MRI of the surgical site at 6 months and 1 year. No systemic cancer surveillance is needed.
